Alentis is widening its therapeutic reach to explore the potential of targeting CLDN1 in fibrosis of other tissues where CLDN1 dysregulation is an established driver of the disease.
Moreover, Alentis’ proprietary discovery cPLS platform (Cellular Prognostic Liver Signature) allows the identification of new targets and supports the fast development of new compounds, which are relevant in fibrosis and solid tumors. We are using our drug discovery platform for pipeline expansion, pioneering a new approach for screening, and the identification of novel targets, biomarkers, and clinical candidates for fibrotic diseases and associated cancers.